Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 6 publications
First-in-human phase 1 trial evaluating safety, pharmacokinetics, and pharmacodynamics of NLRP3 inflammasome inhibitor, GDC-2394, in healthy volunteers.
Journal: Clinical and translational science
Published: April 25, 2023
Effects of inhaled JAK inhibitor GDC-4379 on exhaled nitric oxide and peripheral biomarkers of inflammation.
Journal: Pulmonary pharmacology & therapeutics
Published: December 17, 2021
Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: A randomized, controlled, proof-of-activity trial.
Journal: The Journal of allergy and clinical immunology
Published: November 11, 2020
Antibody-mediated activation of the FGFR1/Klothoβ complex corrects metabolic dysfunction and alters food preference in obese humans.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: November 03, 2020
CX3CL1-Fc treatment prevents atherosclerosis in Ldlr KO mice.
Journal: Molecular metabolism
Published: June 15, 2018
Chronic fractalkine administration improves glucose tolerance and pancreatic endocrine function.
Journal: The Journal of clinical investigation
Published: March 31, 2017
Showing 1-6 of 6
Last Updated: 09/26/2026